/
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline.
12.71% operating margin is respectable but not wide. ROIC at 4.24%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 12.9%, still solid. Margins contracted 4.3pp, which offsets some of the top-line progress.
Operating margin contracted 4.3pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$3.24B
▲ +12.9% YoY
Net Income (TTM)
$269M
▼ -18.3% YoY
Op. Margin
9.72%
▼ -4.3pp YoY
ROIC
2.87%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$767M
▲ +48.7% YoY
Op. Cash Flow (TTM)
$874M
▲ +44.5% YoY
Net Debt
-$792M
Net Cash Position
Cash & Equiv.
$2.22B
5Y CAGR: +11.6%
Continue Research